Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) EPS (Weighted Average and Diluted) (2021 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with $0.07 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 333.33% year-over-year to $0.07, compared with a TTM value of $0.0 through Dec 2025, up 100.87%, and an annual FY2025 reading of $0.0, up 100.87% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.07 for Q4 2025 at Xeris Biopharma Holdings, up from $0.0 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.07 in Q4 2025 and bottomed at -$0.45 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.15, with a median of -$0.11 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) dropped 16.67% in 2024, then skyrocketed 333.33% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.45 in 2021, then soared by 77.78% to -$0.1 in 2022, then dropped by 0.0% to -$0.1 in 2023, then soared by 70.0% to -$0.03 in 2024, then soared by 333.33% to $0.07 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for XERS at $0.07 in Q4 2025, $0.0 in Q3 2025, and -$0.01 in Q2 2025.